|
summary: This study shows that prior IFN-beta-1b treatment does not negatively influence the efficacy, safety, or tolerability of subsequent glatiramer acetate therapy. Switching to glatiramer acetate can benefit patients who discontinue IFN-beta therapy.
author: Zwibel HL
source: Acta Neurol Scand. 2006 Jun;113(6):378-386.
weblink: click here
category: Clinical Trials and Therapeutics
related research news: click here
glossary:
ACE
Glatiramer
Interferon
Intermittent
Multiple sclerosis
Sclerosis
|
